Publications by authors named "G Rozen"
Abstract: Chemotherapeutic agents result in the loss of growing follicles, which can manifest as amenorrhoea. Alkylating chemotherapy (AC) is known to be more gonadotoxic than non-alkylating chemotherapy (NAC). Anti-Müllerian hormone (AMH), an indirect marker of ovarian reserve, and age have been investigated as predictors of ovarian function after chemotherapy; however, little is known about the time to return of menses.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the use of goserelin to prevent treatment-related premature ovarian insufficiency (POI) in young women undergoing chemotherapy for cancer since its approval in Australia in 2018.!* -
- Out of 66 eligible patients, 76% discussed goserelin for POI prevention, and 80% were prescribed it, with nulliparous and younger women being more likely to have these discussions and prescriptions.!* -
- A notable issue found was that 25% of patients did not have discussions about goserelin despite its importance, indicating a need for improving awareness and timely use of the drug among premenopausal women.!*
Article Synopsis
- *A study analyzing hospital data from 2016 to 2020 revealed that while the rate of AF/AFL hospitalizations was stable prior to 2020, it dropped sharply in 2020 alongside an increase in severe outcomes like mortality and stroke.
- *Key factors associated with worse outcomes included older age, ischemic heart disease, chronic kidney disease, and COVID-19 infection itself.
Article Synopsis
- * Analyzed outcomes between patients who received imaging and those who did not, finding no significant differences in complications, recurrence of atrial fibrillation, or re-hospitalization rates after one year.
- * Despite longer procedure times for those who underwent imaging (90 minutes vs. 74.5 minutes), the study concludes that pre-procedural imaging does not impact the safety or efficacy of PVI in managing atrial fibrillation.